Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Subscribe To Our Newsletter & Stay Updated
